EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Arecor Therapeutics's Enterprise Value is £38.46 Mil.
Arecor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £-5.99 Mil. Therefore, Arecor Therapeutics's EV-to-FCF for today is -6.42.
The historical rank and industry rank for Arecor Therapeutics's EV-to-FCF or its related term are showing as below:
LSE:AREC'
s EV-to-FCF Range Over the Past 10 Years
Min: -60.43 Med: -7.16 Max: -3.62
Current: -5.63
During the past 7 years, the highest EV-to-FCF of Arecor Therapeutics was -3.62. The lowest was -60.43. And the median was -7.16.
LSE:AREC's EV-to-FCF is ranked worse than 100% of 379
companies
in the Biotechnology industry
Industry Median: 8.34
vs LSE:AREC: -5.63
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Arecor Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arecor Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Arecor Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's EV-to-FCF falls into.
Arecor Therapeutics's current Enterprise Value is £38.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £-5.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Arecor Therapeutics's PE Ratio for today is calculated as:
Arecor Therapeutics's share price for today is £1.465.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Arecor Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-0.003.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Arecor Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Arecor Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Arecor Therapeutics (LSE:AREC) Business Description
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:AREC has been successfully added to your 